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Abstract: Mitochondria are dynamic organelles that undergo constant fission and fusion. 
Mitochondria dysfunction underlies several human disorders, including Alzheimer’s disease (AD). 
Preservation of mitochondrial dynamics is fundamental for regulating the organelle’s functions. 
Several proteins participate in the regulation of mitochondrial morphology and networks, and 
among these, Mitofusin 2 (Mfn2) has been extensively studied. This review focuses on the role of 
Mfn2 in mitochondrial dynamics and in the crosstalk between mitochondria and the endoplasmic 
reticulum, in particular in AD. Understanding how this protein may be related to AD pathogenesis 
will provide essential information for the development of therapies for diseases linked to disturbed 
mitochondrial dynamics, as in AD. 
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1. Introduction 
Mitochondria are the power plants of the cell. These organelles are involved in the synthesis of 
adenosine triphosphate (ATP), and they are responsible for the balance of nutrient storage for energy 
production. Moreover, mitochondria have a fundamental role in the preservation of the cell’s redox 
balance [1]. In the cell, these organelles form a dynamic and connected system in association with the 
endoplasmic reticulum (ER), which is biochemically and physically linked with the outer membrane 
of mitochondria (OMM). These connections are not arbitrary but occur in specific regions of the ER 
membrane called mitochondria-associated ER membranes (MAM) [2]. Among the numerous proteins 
involved in the link between ER and mitochondria, mitofusin-1 and -2 (Mfn1 and Mfn2), inositol 
1,4,5-triphosphate receptor 3 (IP3R3), and voltage-dependent anion channel 1 (VDAC1) undoubtedly 
play key roles [3,4]. While both Mfn1 and Mfn2 occur in the OMM, only Mfn2 is located in the MAM 
[5]. Mfn1 and Mfn2, together with the optic atrophy-1 (OPA1) protein, are three GTPase dynamin-
like proteins that mediate mitochondrial fusion in the inner and outer membranes of mitochondria 
[6]. The mitofusins are transmembrane proteins that form homo- and heterodimers when the fusion 
process is initialized, extruding the N-terminal GTPase domain that faces the cytoplasm. They use 
their GTPase activity to fuse the OMMs together, while the OPA1 protein controls the fusion of the 
inner membranes of mitochondria [7,8]. If the mitochondrial fusion ability is impaired, the organelles 
show fragmentation and the cell is more vulnerable to apoptosis. In this view, the fusion process may 
be considered as a protective mechanism [9]. On the other hand, mitochondrial fission is important 
for the sequestration and elimination of damaged mitochondria [10]. Several GTPase proteins 
participate in the fission mechanism, such as the dynamin-related protein 1 (Drp1) and the 
mitochondrial fission 1 protein (Fis1), that oligomerizes into a large ring-like complex surrounding 
the fission site along the OMM to obtain two daughter mitochondria [11]. 
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Mitochondrial fission and fusion are maintained in a critical balance susceptible to the 
physiological and pathophysiological changes within the cell (Figure 1) [12]. 
 
Figure 1. Schematic representation of the mitochondrial fusion and fission processes. Mfn1 is 
localized in the outer membrane of mitochondria (OMM), and Mfn2 is localized both at the OMM 
and at the endoplasmic reticulum ER. The ER Mfn2 binds to mitochondrial Mfn1 and Mfn2, regulating 
ER morphology and leading to the formation of interconnected mitochondria. In the fission process, 
Drp1 is mobilized to the OMM from the cytosol and is localized to the sites of organelle division. 
Indeed, when mitochondrial dynamics are impaired, the organelle’s functions, including ATP 
production, calcium (Ca2+) flux, reactive oxygen species (ROS) formation, and apoptosis regulation, 
are compromised [13]. In particular, it seems that an increase in mitochondrial fragmentation is 
connected to ROS production. For example, prolonged exposure to high-glucose conditions results 
in increased ROS production, which could be counteracted by blocking the fission process in the 
mitochondria [14]. Even though the exact mechanisms by which ROS overproduction mediates 
mitochondrial dynamics are not fully understood; impairments in both mitochondrial ultrastructure 
and functions are apparently involved. Indeed, failures in mitochondrial fission and fusion can 
contribute to ultrastructural deficits, impairing also the mitochondrial membrane potential [15,16]. 
Therefore, the balance between mitochondrial fission and fusion can be deregulated by oxidative 
stress that, in turn, could further increase ROS generation. 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by 
impaired cognitive function induced by the deposition of amyloid-β (Aβ) peptide and neurofibrillary 
tangles (NFTs) in the neocortex and hippocampal brain areas. Several studies have focused on the 
pathological causes of aggregation of Aβ and hyperphosphorylation of tau protein, without many 
encouraging results. Mitochondrial dysfunction, which can lead to free radical production, apoptosis, 
impaired glucose metabolism, and ultrastructural and mitochondrial DNA (mtDNA) alterations, is 
an early feature of AD pathogenesis and probably occurs prior to the development of Aβ plaque 
formation [17,18]. In a vicious cycle, impaired mitochondrial function leads to increased oxidative 
stress that enhances Aβ production [19]. In AD brains, ultrastructural alterations of the mitochondria 
(i.e., size and shape) could cause a failure in the fusion mechanism [20]. Moreover, similar 
mitochondrial changes occur in peripheral cells, such as fibroblasts, in patients with a sporadic form 
of AD [21]. In addition, oxidative stress is one of the hallmarks of AD pathogenesis, and the oxidative 
damage occurs in the early stages of the disease. 
Considering the key role of oxidative stress in AD progression and mitochondrial dysfunction, 
the aim of the present review is to outline the recent knowledge about the role of the fusion protein 
Mfn2 in AD onset and evolution. 
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2. The Crosstalk between Mitochondria and ER in AD 
Mitochondria are not only responsible for cellular energy production but also have a 
considerable role in the regulation of Ca2+ flux in the ER. It has been demonstrated that marked 
changes to intracellular Ca2+ signaling precede neuronal death and cognitive deterioration in AD [22]. 
The modulation of intracellular Ca2+ by the ER has been studied since an increase in cytosolic Ca2+ 
levels was observed in fibroblasts from asymptomatic patients at risk for AD after treatment with 
bradykinin, a G-protein-coupled receptor agonist [23]. Mitochondria play a double-faced role in 
oxidative stress modulation. Indeed, mitochondria represent a source of ROS, but at the same time 
they are an antioxidant system [24]. It is known that different proteins promote the physical and 
functional tethering between mitochondria and the ER and that altered activity of these proteins may 
be involved in disease onset. Therefore, it is not unexpected that alterations in ER–mitochondria 
connections can lead to the progression of diseases such as AD. Interestingly, presenilin 2 (PS2) and 
Mfn2 increase the number of contact sites [25]. PSs are fundamental components involved in the 
production of Aβ peptides and in Ca2+ homeostasis. Mutations in the gene encoding for PS2 are the 
most prevalent cause of the familial form of AD (FAD). In particular, it has been demonstrated that 
ER–mitochondria binding and the Ca2+ flux are increased in cells with a FAD mutation in PS2 [26,27]. 
Moreover, there is also an involvement of ER and mitochondria in the sporadic form of AD [28]. An 
interesting study conducted by Filadi et al. showed that PS2 requires the expression of Mfn2 to 
modulate ER–mitochondria tethering. Functional and biochemical evidence indicates that PS2, in 
wild type and FAD models, decreases the ER–mitochondria distance to promote Ca2+ flux through 
the interaction with Mfn2 at both sides of MAM domains. In contrast, Mfn2 can reduce the coupling 
even without PS2. Filadi et al. also highlighted that FAD-PS2 mutants are more enriched in MAMs 
than wild type PS2, forming more PS2–Mfn2 complexes, which could indicate several functional 
consequences [25]. In addition, different studies have shown that amyloid precursor protein (APP) 
mutants or exposure to soluble oligomeric Aβ causes changes in the expression of mitochondrial 
fission and fusion proteins, leading to an increase of mitochondrial fragmentation in neuronal cells 
along with neuronal deficits [29–31]. To address the critical role of disrupted mitochondrial fusion in 
neurodegeneration and other AD-related disorders, Jiang and colleagues knocked out Mfn2 in the 
hippocampus and cortex of mice and found that this ablation caused neuronal degeneration in vivo 
in a temporal order, and the pathological changes that they have highlighted are also seen during AD 
progression. Their findings do not necessarily suggest that the pathological events occur at a similar 
temporal order in the AD brain; however, they propose that altered mitochondrial dynamics could 
contribute to several pathological events in AD [29]. 
Mfn2 can be considered a mitochondria-shaping protein involved in the regulation of ER 
morphology [5]. In the ER, Mfn2 has two conformations, one that allows the interaction with the 
opposite Mfn’s binding site and the other that avoids possible interactions of Mfns with Mfn1 or 
Mfn2-partner proteins on the OMM to regulate Ca2+ homeostasis [7]. Moreover, silencing or ablation 
of Mfn2 interferes with ER morphology and disrupts the connections with mitochondria, diminishing 
the efficiency of Ca2+ uptake [5]. 
Increased ER–mitochondria coupling has been reported in different AD models. Hedskog et al. 
demonstrated a significant raise in the expression of MAM proteins and in the number of contacts 
between the ER and mitochondria in the postmortem AD brain. These results were also confirmed in 
an APP Swe/L mouse model, as well as after the treatment of primary hippocampal neurons with Aβ. 
Moreover, the increasing connections between the two organelles after exposure to Aβ caused an 
elevated flux of Ca2+ from the ER to mitochondria in neuroblastoma cells [32]. 
In a study conducted by Leal et al. in 2016, siRNA knockdown of Mfn2 increased ER–
mitochondria tethering, leading to an elevated Ca2+ flux between the organelles. Interestingly, the 
downregulation of Mfn2 decreased the levels of Aβ by around 40%, impairing γ-secretase activity 
[33]. They showed that the increase of ER–mitochondria contacts impaired γ-secretase activity, 
leading to reduced Aβ levels. Thus, these findings may introduce new strategies to regulate γ-
secretase activity by the modulation of MAM function and ER–mitochondria communication. 
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3. Mitochondrial Dysfunction in Alzheimer’s Disease 
Normal mitochondrial activity is fundamental to maintain the correct polarity in neurons [34]. 
As a consequence, mitochondrial dysfunction promotes oxidative stress, aging, and 
neurodegeneration [24]. Moreover, Aβ overproduction increases mitochondrial fission and, 
simultaneously, decreases mitochondrial fusion activity, causing mitochondrial fragmentation and 
neuronal death [35]. In 2015, Park et al. conducted a study examining the correlation between the 
presence of Aβ oligomers (AβOs) and the changes observed in mitochondrial morphology in N2a 
cells. The results suggested that intracellular AβOs not only cause mitochondrial fragmentation, 
reducing the expression of the mitochondrial Mfns, but also lead to mitochondrial functional defects 
[36]. The authors also proposed that the decrease in Mfn2 expression levels can be considered more 
pathologically relevant than the decrease in Mfn1 expression in the mitochondrial fragmentation 
event, as demonstrated by the inhibition of AβO-mediated cell death after the overexpression of Mfn2 
[36]. Furthermore, Gan et al. used cytoplasmic hybrid (cybrid) cells obtained from neuronal cells (SH-
SY5Y) and mitochondria from AD or age-matched healthy human control subjects to evaluate the 
mechanisms that underlie AD-specific mitochondrial defects [37]. In this study, AD cybrids showed 
several features that contribute to the pathogenesis of AD, such as a decrease in respiratory chain 
activity and an increase of ROS production. In particular, Drp1 translocation to mitochondria was 
increased and Mfn2 expression was decreased in AD cybrid cells, suggesting an imbalance of 
mitochondrial dynamics, which may lead to the mitochondrial fragmentation observed in AD 
cybrids. 
Growing evidence suggests the possibility that mitochondria can mediate or even initiate the 
pathogenesis of the sporadic form of AD. This hypothesis posits that mitochondrial impairment exists 
independently of Aβ deposition and probably precedes it [38,39]. A recent study used accelerated 
senescence OXYS rats, which simulate the main features of the sporadic form of AD, to explore the 
mitochondrial ultrastructure of pyramidal neurons of the CA1 region of the hippocampus and 
measured the levels of the key proteins involved in mitochondrial dynamics (Mfn1, Mfn2, and Drp1) 
[40]. The results highlighted a shift from mitochondrial fusion toward fission from 4 to 24 months of 
age, as confirmed by increasing Drp1 content and a decreasing Mfn2/Drp1 ratio. Indeed, this 
imbalance is a feature of several models of neurodegeneration. 
Interestingly, Wang et al. proved that the expression of mitochondrial fusion proteins is reduced 
in the AD brain as compared to age-matched normal subjects, and especially in the hippocampal 
region, the region most involved in the pathology [41]. Moreover, in 2011 Manczak et al. evaluated 
the nature of AβOs and mitochondrial proteins in post-mortem AD brain tissues at different stages 
of the pathology. The results showed a reduction in the expression levels of mitochondrial fusion 
genes (Mfn1, Mfn2, and OPA1) and an increase of fission genes (Drp1), as compared to healthy 
controls [42]. Accordingly, in 12 month-old transgenic mice (Tg2576 line), mitochondrial fusion 
proteins were significantly decreased (Mfn1, Mfn2, and Opa1) in hippocampal tissues. These 
observations demonstrated that deposition of hippocampal Aβ induced alterations in mitochondrial 
dynamics in these mice [43]. On the other hand, the notion that the increased expression of Mfn2 
leads to the inhibition of AβO deposition suggests the potential protective role of this fusion protein 
in AD. Accordingly, the gene for Mfn2 is located on the short arm of chromosome 1 (1p36), which 
has been widely documented as a locus associated with AD [44]. 
Mutations in the Mfn2 gene cause an autosomal dominant disease called Charcot–Marie–Tooth 
disease subtype 2A (CMT2A), which is characterized by motor and sensory peripheral neuropathy. 
Although CMT2A mainly affects the peripheral nervous system, recent evidence indicates that 
CMT2A patients might have brain pathologies [45,46]. Supporting this view, Kim et al. conducted a 
preliminary study on the Korean population to investigate the relation between Mfn2 and AD. This 
study was focused on one coding single nucleotide polymorphism (SNP) of the Mfn2 gene, and the 
results showed that the SNP analyzed (rs1042837) was significantly correlated with the risk of AD in 
the Korean population [6]. 
Recently, Zhang et al. investigated the involvement of Mfn2 deregulation and post-
transcriptional regulation of microRNAs (miRNAs) in AD, using the senescence-accelerated mouse 
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prone 8 (SAMP8) model and transfected HT-22 cells. MiRNAs are a class of small non-coding RNA 
molecules able to control post-transcriptional gene expression by the inhibition or the degradation of 
the target mRNAs. Zhang et al. confirmed that mRNA levels of Mfn2 were reduced in the cortical 
and hippocampal areas of SAMP8 mice, while the mRNA protein levels were decreased only in the 
hippocampus of SAMP8 mice. In particular, the Mfn2 protein seems to be located mainly in the CA3 
subfield of the hippocampus, an area closely associated with learning and memory activities. 
Moreover, the authors not only proved that the expression of miRNA-195 was upregulated in the 
hippocampus of SAMP8 mice but also showed that it was an upstream regulator of Mfn2 expression 
during the evolution of AD [47]. Unfortunately, the study did not investigate in vivo the effects of 
miRNA-195 related to Mfn2 on cognitive function. 
To the best of our knowledge, there is only one study that does not confirm what was discussed 
above. Xu et al. investigated the expression of mitochondrial proteins with AD progression in 
APP/PS1 mice and found differences in mitochondrial fusion and fission proteins as compared to 
age-matched C57BL/6 mice. The results showed a significant increase of fission and fusion protein 
(Drp1, Fis1, Mfn2) levels in 3 month-old APP/PS1 mice [48]. Interestingly, with disease progression, 
the level of Mfn2 expression increased compared to wild-type mice. These data suggest that aberrant 
mitochondrial dynamics may be considered an early event in AD progression [48]. 
Mild cognitive impairment (MCI) is characterized by a progressive decline of cognitive abilities 
and usually is considered a prodromal syndrome that ultimately leads to early dementia, including 
AD [49]. Interestingly, MCI patients show mitochondrial alterations comparable to those observed in 
AD patients [50]. Gan et al. used the cybrid model with mitochondria derived from MCI patients that 
revealed a significant rise in Mfn2 expression, but not in Drp1 as compared to non-MCI controls [51]. 
These data corroborate the hypothesis that the enhanced mitochondrial fusion could be considered 
an early step in AD, and altered levels of Mfn2 contribute consistently to this event. The results 
obtained by Gan et al. demonstrated that the upregulation of Mfn2 may represent a response to 
cellular stress, as also suggested by Sugioka et al. [52]. One possibility that merits further 
investigation is the idea that Mfn2 is upregulated in MCI; in AD, the protein is downregulated, 
indicating that the earliest stages of the disease represent the time window available for a potential 
therapy that targets Mfn2. 
4. Mfn2 as A Potential Target in Alzheimer’s Disease 
Research on AD therapies has resulted in only a few symptomatic drugs, which are not able to 
halt or slow the progression of the disease. Mitochondrial dynamics is crucial in neurons because it 
allows the replacement of the damaged mitochondria in non-proliferating cells. Mitochondria are 
undoubtedly constantly exposed to the oxidative stress caused by the production of ROS, and they 
accumulate mtDNA damage that leads to progressive energy production failure. In addition, the 
accumulation of misfolded proteins, such as the Aβ peptide, in mitochondria induces impairments 
in mitochondrial bioenergetics and dynamics and an increased sensitivity to apoptosis [53]. In this 
review, we have illustrated the fundamental role of Mfn2 in mitochondrial function in health and 
disease, in particular in AD. Recently, different authors have indicated how perturbations in 
mitochondrial dynamics, particularly in fission and fusion proteins, Drp1, Fis1, OPA1, and Mfn2, can 
contribute to neuropathology [54–56]. 
Presumably, neuroprotective strategies may target the stabilization of mitochondrial dynamics. 
Preclinical studies about the amelioration of mitochondrial dysfunction and associated synaptic 
failures, as well as cognitive impairments, have been reported for different polyphenols and other 
natural compounds and for some new synthetic drugs. This research aimed to identify possible 
targets and/or to investigate effects on specific aspects of mitochondrial function. Few studies have 
considered Mfn2 as a potential target for AD treatment. Gan et al. demonstrated that treatment with 
an antioxidant compound (probucol) significantly increased Mfn2 and decreased Drp1 expression in 
cybrid cells obtained from neurons containing mitochondria from human AD or MCI patients. These 
results showed that antioxidants are able to reverse the impaired fission and fusion dynamics in 
mitochondria [37,51]. 
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An additional study conducted by Chen et al. evaluated the potential beneficial effect of 
treatment with icariin in hippocampal neurons obtained from triple-transgenic mice (3xTg-AD) [57]. 
Icariin is isolated from the Chinese herb epimedium and is used as an antirheumatic that has already 
shown consistent efficacy in AD models [58]. The authors demonstrated that treatment with icariin 
was able to reduce Drp1 and increase Mfn2 levels in AD neurons, likely maintaining healthy 
mitochondria through the modulation of their dynamics [57]. Moreover, Chimeh et al. elucidated the 
cytoprotective activity of a novel compound against oxidative damage in mouse hippocampal HT-22 
cells. They observed that the molecule protects by decreasing ROS generation and mitochondrial 
membrane hyperpolarization. In that study, the expression of Mfn2 was increased while OPA1 
expression was unchanged, thus confirming the key role of this protein in neuroprotective 
mechanisms [59]. 
Moreover, Zafeer et al. [60] evaluated the effect of trans-ferulic acid (FA) on the intracerebral-
ventricular streptozocin (ICV-STZ) rat model. They found an increase and decrease in mitochondrial 
Drp1 and Mfn2 protein levels, respectively. As already described, a balance between both processes 
is essential for maintaining mitochondrial health in neurons. In their model, the decrease of Mfn2 
induced mitochondrial dysfunction and apoptosis. Interestingly, FA administration was able to 
reduce apoptotic cell loss through the management of mitochondrial abnormalities associated with 
neurodegenerative damage. 
To search for small molecules that inhibit mitochondrial division, Cassidy-Stone and colleagues 
used yeast screens of chemical libraries and identified a specific inhibitor called mdivi-1 [61]. Mdivi-
1 selectively inhibits the GTPase activity of dynamin-1 (Dnm1) by blocking the self-assembly of 
Dnm1. It also prevents mitochondrial fission in mammalian cells by blocking Drp1 assembly. It has 
been demonstrated that cells treated with mdivi-1 are resistant to apoptosis upon apoptotic 
challenges, presumably by decreasing mitochondrial membrane permeabilization. Recently, Reddy 
et al. [62] demonstrated that mdivi-1 protects mitochondrial structure and function by regulating 
mitochondrial fission and fusion genes, such as Mfn2, in N2a cells treated with Aβ1–42 peptides. 
The pathway that regulates Aβ production is well known; however, the regulation of this 
process is not fully understood. γ-secretase activity and consequent Aβ production are finely 
regulated by several proteins whose mechanisms need to be clarified. Mfn2 is one of these proteins, 
as shown by Leal et al. [33]. Although ablation of Mfn2 is not a reasonable treatment strategy because 
of the role of this protein in mitochondrial stability, their data showed that the modulation of ER–
mitochondria interaction affects γ-secretase function. This finding may introduce new approaches to 
regulate γ-secretase activity besides γ-secretase inhibitors and modulators. 
5. Conclusions 
Mitochondrial function is considerably impaired in AD, and there is rising interest in 
understanding how to inhibit neurodegeneration by targeting altered mitochondrial activities. The 
accurate regulation of mitochondrial turnover, responsible for the elimination of dysfunctional 
mitochondria and the maintenance of functional ones in response to stresses, may be crucial to control 
neurodegeneration in AD. Indeed, it is likely that mitochondrial homeostasis reflects an efficient 
bioenergetic metabolism as well as mitochondrial dynamics—two faces of the same coin. In this 
context, the role of Mfn2 is essential for preserving proper mitochondrial network dynamics. Thus, 
novel therapeutics able to target mitochondria should have the potential to act simultaneously on the 
two aspects of mitochondrial function. Further studies are needed to discover new promising agents 
capable of selectively targeting the mitochondria, and in particular Mfn2. 
Funding: This research was funded by the Ministero dell’Istruzione, dell’Università e della Ricerca (MIUR), 
PRIN 2015 (Prot. 20152HKF3Z) and Fondazione del Monte di Bologna e Ravenna. 
Conflicts of Interest: The authors declare no conflict of interest. 
  
J. Clin. Med. 2020, 9, 126 7 of 10 
 
References 
1. Mazat, J.-P.; Ransac, S.; Heiske, M.; Devin, A.; Rigoulet, M. Mitochondrial energetic metabolism-some 
general principles. IUBMB Life 2013, 65, 171–179, doi:10.1002/iub.1138. 
2. Raturi, A.; Simmen, T. Where the endoplasmic reticulum and the mitochondrion tie the knot: The 
mitochondria-associated membrane (MAM). Biochim. Biophys. Acta Mol. Cell Res. 2013, 1833, 213–224, 
doi:10.1016/j.bbamcr.2012.04.013. 
3. Merkwirth, C.; Langer, T. Mitofusin 2 Builds a Bridge between ER and Mitochondria. Cell 2008, 135, 1165–
1167, doi:10.1016/j.cell.2008.12.005. 
4. de Brito, O.M.; Scorrano, L. An intimate liaison: Spatial organization of the endoplasmic reticulum–
mitochondria relationship. EMBO J. 2010, 29, 2715–2723, doi:10.1038/emboj.2010.177. 
5. de Brito, O.M.; Scorrano, L. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 2008, 456, 
605–610, doi:10.1038/nature07534. 
6. Kim, Y.J.; Park, J.K.; Kang, W.S.; Kim, S.K.; Han, C.; Na, H.R.; Park, H.J.; Kim, J.W.; Kim, Y.Y.; Park, M.H.; 
et al. Association between Mitofusin 2 Gene Polymorphisms and Late-Onset Alzheimer’s Disease in the 
Korean Population. Psychiatry Investig. 2017, 14, 81–85, doi:10.4306/pi.2017.14.1.81. 
7. Ishihara, N.; Eura, Y.; Mihara, K. Mitofusin 1 and 2 play distinct roles in mitochondrial fusion reactions via 
GTPase activity. J. Cell Sci. 2004, 117, 6535–6546, doi:10.1242/jcs.01565. 
8. Hoppins, S.; Lackner, L.; Nunnari, J. The Machines that Divide and Fuse Mitochondria. Annu. Rev. Biochem. 
2007, 76, 751–780, doi:10.1146/annurev.biochem.76.071905.090048. 
9. Santos, R.X.; Correia, S.C.; Wang, X.; Perry, G.; Smith, M.A.; Moreira, P.I.; Zhu, X. A Synergistic Dysfunction 
of Mitochondrial Fission/Fusion Dynamics and Mitophagy in Alzheimer’s Disease. J. Alzheimer’s Dis. 2010, 
20, S401–S412, doi:10.3233/JAD-2010-100666. 
10. Twig, G.; Elorza, A.; Molina, A.J.A.; Mohamed, H.; Wikstrom, J.D.; Walzer, G.; Stiles, L.; Haigh, S.E.; Katz, 
S.; Las, G.; et al. Fission and selective fusion govern mitochondrial segregation and elimination by 
autophagy. EMBO J. 2008, 27, 433–446, doi:10.1038/sj.emboj.7601963. 
11. Su, B.; Wang, X.; Zheng, L.; Perry, G.; Smith, M.A.; Zhu, X. Abnormal mitochondrial dynamics and 
neurodegenerative diseases. Biochim. Biophys. Acta 2010, 1802, 135–142, doi:10.1016/j.bbadis.2009.09.013. 
12. Yan, M.H.; Wang, X.; Zhu, X. Mitochondrial defects and oxidative stress in Alzheimer disease and 
Parkinson disease. Free Radic. Biol. Med. 2013, 62, 90–101, doi:10.1016/j.freeradbiomed.2012.11.014. 
13. Benard, G.; Bellance, N.; James, D.; Parrone, P.; Fernandez, H.; Letellier, T.; Rossignol, R. Mitochondrial 
bioenergetics and structural network organization. J. Cell Sci. 2007, 120, 838–848, doi:10.1242/jcs.03381. 
14. Yu, T.; Robotham, J.L.; Yoon, Y. Increased production of reactive oxygen species in hyperglycemic 
conditions requires dynamic change of mitochondrial morphology. Proc. Natl. Acad. Sci. USA 2006, 103, 
2653–2658, doi:10.1073/pnas.0511154103. 
15. Chen, H.; McCaffery, J.M.; Chan, D.C. Mitochondrial Fusion Protects against Neurodegeneration in the 
Cerebellum. Cell 2007, 130, 548–562, doi:10.1016/j.cell.2007.06.026. 
16. Darshi, M.; Mendiola, V.L.; Mackey, M.R.; Murphy, A.N.; Koller, A.; Perkins, G.A.; Ellisman, M.H.; Taylor, 
S.S. ChChd3, an Inner Mitochondrial Membrane Protein, Is Essential for Maintaining Crista Integrity and 
Mitochondrial Function. J. Biol. Chem. 2011, 286, 2918–2932, doi:10.1074/jbc.M110.171975. 
17. Zhu, X.; Perry, G.; Smith, M.A.; Wang, X. Abnormal Mitochondrial Dynamics in the Pathogenesis of 
Alzheimer’s Disease. J. Alzheimer’s Dis. 2012, 33, S253–S262, doi:10.3233/JAD-2012-129005. 
18. Hroudová, J.; Singh, N.; Fišar, Z. Mitochondrial Dysfunctions in Neurodegenerative Diseases: Relevance 
to Alzheimer’s Disease. Biomed. Res. Int. 2014, 2014, 1–9, doi:10.1155/2014/175062. 
19. Leuner, K.; Schulz, K.; Schütt, T.; Pantel, J.; Prvulovic, D.; Rhein, V.; Savaskan, E.; Czech, C.; Eckert, A.; 
Müller, W.E. Peripheral Mitochondrial Dysfunction in Alzheimer’s Disease: Focus on Lymphocytes. Mol. 
Neurobiol. 2012, 46, 194–204, doi:10.1007/s12035-012-8300-y. 
20. Baloyannis, S.J. Mitochondrial alterations in Alzheimer’s disease. J. Alzheimer’s Dis. 2006, 9, 119–126. 
21. Wang, X.; Su, B.; Fujioka, H.; Zhu, X. Dynamin-Like Protein 1 Reduction Underlies Mitochondrial 
Morphology and Distribution Abnormalities in Fibroblasts from Sporadic Alzheimer’s Disease Patients. 
Am. J. Pathol. 2008, 173, 470–482, doi:10.2353/ajpath.2008.071208. 
22. Bezprozvanny, I.; Mattson, M.P. Neuronal calcium mishandling and the pathogenesis of Alzheimer’s 
disease. Trends Neurosci. 2008, 31, 454–463, doi:10.1016/j.tins.2008.06.005. 
J. Clin. Med. 2020, 9, 126 8 of 10 
 
23. Etcheberrigaray, R.; Hirashima, N.; Nee, L.; Prince, J.; Govoni, S.; Racchi, M.; Tanzi, R.E.; Alkon, D.L. 
Calcium responses in fibroblasts from asymptomatic members of Alzheimer’s disease families. Neurobiol. 
Dis. 1998, 5, 37–45, doi:10.1006/nbdi.1998.0176. 
24. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 
2006, 443, 787–795, doi:10.1038/nature05292. 
25. Filadi, R.; Greotti, E.; Turacchio, G.; Luini, A.; Pozzan, T.; Pizzo, P. Presenilin 2 Modulates Endoplasmic 
Reticulum-Mitochondria Coupling by Tuning the Antagonistic Effect of Mitofusin 2. Cell Rep. 2016, 15, 
2226–2238, doi:10.1016/j.celrep.2016.05.013. 
26. Zampese, E.; Fasolato, C.; Kipanyula, M.J.; Bortolozzi, M.; Pozzan, T.; Pizzo, P. Presenilin 2 modulates 
endoplasmic reticulum (ER)-mitochondria interactions and Ca2+ cross-talk. Proc. Natl. Acad. Sci. USA 2011, 
108, 2777–2782, doi:10.1073/pnas.1100735108. 
27. Nelson, O.; Tu, H.; Lei, T.; Bentahir, M.; de Strooper, B.; Bezprozvanny, I. Familial Alzheimer disease–
linked mutations specifically disrupt Ca2+ leak function of presenilin 1. J. Clin. Investig. 2007, 117, 1230–
1239, doi:10.1172/JCI30447. 
28. Area-Gomez, E.; del Carmen Lara Castillo, M.; Tambini, M.D.; Guardia-Laguarta, C.; de Groof, A.J.C.; 
Madra, M.; Ikenouchi, J.; Umeda, M.; Bird, T.D.; Sturley, S.L.; et al. Upregulated function of mitochondria-
associated ER membranes in Alzheimer disease. EMBO J. 2012, 31, 4106–4123, doi:10.1038/emboj.2012.202. 
29. Jiang, S.; Nandy, P.; Wang, W.; Ma, X.; Hsia, J.; Wang, C.; Wang, Z.; Niu, M.; Siedlak, S.L.; Torres, S.; et al. 
Mfn2 ablation causes an oxidative stress response and eventual neuronal death in the hippocampus and 
cortex. Mol. Neurodegener. 2018, 13, 5, doi:10.1186/s13024-018-0238-8. 
30. Wang, X.; Su, B.; Siedlak, S.L.; Moreira, P.I.; Fujioka, H.; Wang, Y.; Casadesus, G.; Zhu, X. Amyloid—
Overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial 
fission/fusion proteins. Proc. Natl. Acad. Sci. USA 2008, 105, 19318–19323, doi:10.1073/pnas.0804871105. 
31. Du, H.; Guo, L.; Yan, S.; Sosunov, A.A.; McKhann, G.M.; ShiDu Yan, S. Early deficits in synaptic 
mitochondria in an Alzheimer’s disease mouse model. Proc. Natl. Acad. Sci. USA 2010, 107, 18670–18675, 
doi:10.1073/pnas.1006586107. 
32. Hedskog, L.; Pinho, C.M.; Filadi, R.; Ronnback, A.; Hertwig, L.; Wiehager, B.; Larssen, P.; Gellhaar, S.; 
Sandebring, A.; Westerlund, M.; et al. Modulation of the endoplasmic reticulum-mitochondria interface in 
Alzheimer’s disease and related models. Proc. Natl. Acad. Sci. USA 2013, 110, 7916–7921, 
doi:10.1073/pnas.1300677110. 
33. Leal, N.S.; Schreiner, B.; Pinho, C.M.; Filadi, R.; Wiehager, B.; Karlström, H.; Pizzo, P.; Ankarcrona, M. 
Mitofusin-2 knockdown increases ER-mitochondria contact and decreases amyloid β-peptide production. 
J. Cell. Mol. Med. 2016, 20, 1686–1695, doi:10.1111/jcmm.12863. 
34. Hollenbeck, P.J.; Saxton, W.M. The axonal transport of mitochondria. J. Cell Sci. 2005, 118, 5411–5419, 
doi:10.1242/jcs.02745. 
35. Cha, M.-Y.; Han, S.-H.; Son, S.M.; Hong, H.-S.; Choi, Y.-J.; Byun, J.; Mook-Jung, I. Mitochondria-Specific 
Accumulation of Amyloid β Induces Mitochondrial Dysfunction Leading to Apoptotic Cell Death. PLoS 
ONE 2012, 7, e34929, doi:10.1371/journal.pone.0034929. 
36. Park, J.; Choi, H.; Min, J.-S.; Kim, B.; Lee, S.-R.; Yun, J.W.; Choi, M.-S.; Chang, K.-T.; Lee, D.-S. Loss of 
mitofusin 2 links beta-amyloid-mediated mitochondrial fragmentation and Cdk5-induced oxidative stress 
in neuron cells. J. Neurochem. 2015, 132, 687–702, doi:10.1111/jnc.12984. 
37. Gan, X.; Huang, S.; Wu, L.; Wang, Y.; Hu, G.; Li, G.; Zhang, H.; Yu, H.; Swerdlow, R.H.; Chen, J.X.; et al. 
Inhibition of ERK-DLP1 signaling and mitochondrial division alleviates mitochondrial dysfunction in 
Alzheimer’s disease cybrid cell. Biochim. Biophys. Acta 2014, 1842, 220–231, doi:10.1016/j.bbadis.2013.11.009. 
38. Gao, J.; Wang, L.; Liu, J.; Xie, F.; Su, B.; Wang, X. Abnormalities of Mitochondrial Dynamics in 
Neurodegenerative Diseases. Antioxidants 2017, 6, 25, doi:10.3390/antiox6020025. 
39. Swerdlow, R.H.; Burns, J.M.; Khan, S.M. The Alzheimer’s Disease Mitochondrial Cascade Hypothesis. J. 
Alzheimer’s Dis. 2010, 20, S265–S279, doi:10.3233/JAD-2010-100339. 
40. Tyumentsev, M.A.; Stefanova, N.A.; Muraleva, N.A.; Rumyantseva, Y.V.; Kiseleva, E.; Vavilin, V.A.; 
Kolosova, N.G. Mitochondrial Dysfunction as a Predictor and Driver of Alzheimer’s Disease-Like 
Pathology in OXYS Rats. J. Alzheimer’s Dis. 2018, 63, 1075–1088, doi:10.3233/JAD-180065. 
41. Wang, X.; Su, B.; Lee, H.-G.; Li, X.; Perry, G.; Smith, M.A.; Zhu, X. Impaired Balance of Mitochondrial 
Fission and Fusion in Alzheimer’s Disease. J. Neurosci. 2009, 29, 9090–9103, doi:10.1523/JNEUROSCI.1357-
09.2009. 
J. Clin. Med. 2020, 9, 126 9 of 10 
 
42. Manczak, M.; Calkins, M.J.; Reddy, P.H. Impaired mitochondrial dynamics and abnormal interaction of 
amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: 
Implications for neuronal damage. Hum. Mol. Genet. 2011, 20, 2495–2509, doi:10.1093/hmg/ddr139. 
43. Manczak, M.; Kandimalla, R.; Yin, X.; Reddy, P.H. Hippocampal mutant APP and amyloid beta-induced 
cognitive decline, dendritic spine loss, defective autophagy, mitophagy and mitochondrial abnormalities 
in a mouse model of Alzheimer’s disease. Hum. Mol. Genet. 2018, 27, 1332–1342, doi:10.1093/hmg/ddy042. 
44. Hiltunen, M.; Mannermaa, A.; Thompson, D.; Easton, D.; Pirskanen, M.; Helisalmi, S.; Koivisto, A.M.; 
Lehtovirta, M.; Ryynänen, M.; Soininen, H. Genome-wide linkage disequilibrium mapping of late-onset 
Alzheimer’s disease in Finland. Neurology 2001, 57, 1663–1668, doi:10.1212/wnl.57.9.1663. 
45. Chung, K.W.; Suh, B.C.; Cho, S.Y.; Choi, S.K.; Kang, S.H.; Yoo, J.H.; Hwang, J.Y.; Choi, B.O. Early-onset 
Charcot-Marie-Tooth patients with mitofusin 2 mutations and brain involvement. J. Neurol. Neurosurg. 
Psychiatry 2010, 81, 1203–1206, doi:10.1136/jnnp.2009.181669. 
46. Bo, R.D.; Moggio, M.; Rango, M.; Bonato, S.; D’Angelo, M.G.; Ghezzi, S.; Airoldi, G.; Bassi, M.T.; Guglieri, 
M.; Napoli, L.; et al. Mutated mitofusin 2 presents with intrafamilial variability and brain mitochondrial 
dysfunction. Neurology 2008, 71, 1959–1966, doi:10.1212/01.wnl.0000327095.32005.a4. 
47. Zhang, R.; Zhou, H.; Jiang, L.; Mao, Y.; Cui, X.; Xie, B.; Cui, D.; Wang, H.; Zhang, Q.; Xu, S. MiR-195 
dependent roles of mitofusin2 in the mitochondrial dysfunction of hippocampal neurons in SAMP8 mice. 
Brain Res. 2016, 1652, 135–143, doi:10.1016/j.brainres.2016.09.047. 
48. Xu, L.-L.; Shen, Y.; Wang, X.; Wei, L.-F.; Wang, P.; Yang, H.; Wang, C.-F.; Xie, Z.-H.; Bi, J.-Z. Mitochondrial 
dynamics changes with age in an APPsw/PS1dE9 mouse model of Alzheimer’s disease. Neuroreport 2017, 
28, 222–228, doi:10.1097/WNR.0000000000000739. 
49. Karakaya, T.; Fußer, F.; Schroder, J.; Pantel, J. Pharmacological Treatment of Mild Cognitive Impairment 
as a Prodromal Syndrome of Alzheimer’s Disease. Curr. Neuropharmacol. 2013, 11, 102–108, 
doi:10.2174/157015913804999487. 
50. Silva DF, Santana I, Esteves AR, Baldeiras I,. Arduino DM, Oliveira CR, Cardoso, SM. Prodromal Metabolic 
Phenotype in MCI Cybrids: Implications for Alzheimer’s Disease. Curr. Alzheimer Res. 2013, 10, 180–190, 
doi:10.2174/1567205011310020008. 
51. Gan, X.; Wu, L.; Huang, S.; Zhong, C.; Shi, H.; Li, G.; Yu, H.; Howard Swerdlow, R.; Xi Chen, J.; Yan, S.S. 
Oxidative stress-mediated activation of extracellular signal-regulated kinase contributes to mild cognitive 
impairment-related mitochondrial dysfunction. Free Radic. Biol. Med. 2014, 75, 230–240, 
doi:10.1016/j.freeradbiomed.2014.07.021. 
52. Sugioka, R.; Shimizu, S.; Tsujimoto, Y. Fzo1, a Protein Involved in Mitochondrial Fusion, Inhibits 
Apoptosis. J. Biol. Chem. 2004, 279, 52726–52734, doi:10.1074/jbc.M408910200. 
53. Karbowski, M.; Neutzner, A. Neurodegeneration as a consequence of failed mitochondrial maintenance. 
Acta Neuropathol. 2012, 123, 157–171. 
54. Golpich, M.; Amini, E.; Mohamed, Z.; Azman Ali, R.; Mohamed Ibrahim, N.; Ahmadiani, A. Mitochondrial 
Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment. CNS Neurosci. 
Ther. 2017, 23, 5–22. 
55. Reddy, P.H.; Manczak, M.; Yin, X.L.; Reddy, A.P. Synergistic Protective Effects of Mitochondrial Division 
Inhibitor 1 and Mitochondria-Targeted Small Peptide SS31 in Alzheimer’s Disease. J. Alzheimer’s Dis. 2018, 
62, 1549–1565, doi:10.3233/JAD-170988. 
56. Alexiou, A.; Soursou, G.; Chatzichronis, S.; Gasparatos, E.; Kamal, M.A.; Yarla, N.S.; Perveen, A.; Barreto, 
G.E.; Ashraf, G.M. Role of GTPases in the Regulation of Mitochondrial Dynamics in Alzheimer’s Disease 
and CNS-Related Disorders. Mol. Neurobiol. 2019, 56, 4530–4538. 
57. Chen, Y.; Han, S.; Huang, X.; Ni, J.; He, X. The Protective Effect of Icariin on Mitochondrial Transport and 
Distribution in Primary Hippocampal Neurons from 3× Tg-AD Mice. Int. J. Mol. Sci. 2016, 17, 
doi:10.3390/ijms17020163. 
58. Ma, H.; He, X.; Yang, Y.; Li, M.; Hao, D.; Jia, Z. The genus Epimedium: An ethnopharmacological and 
phytochemical review. J. Ethnopharmacol. 2011, 134, 519–541, doi:10.1016/j.jep.2011.01.001. 
59. Chimeh, U.; Zimmerman, M.A.; Gilyazova, N.; Li, P.A. B355252, a novel small molecule, confers 
neuroprotection against cobalt chloride toxicity in mouse hippocampal cells through altering 
mitochondrial dynamics and limiting autophagy induction. Int. J. Med. Sci. 2018, 15, 1384–1396, 
doi:10.7150/ijms.24702. 
J. Clin. Med. 2020, 9, 126 10 of 10 
 
60. Zafeer, M.F.; Firdaus, F.; Anis, E.; Mobarak Hossain, M. Prolong treatment with Trans-ferulic acid mitigates 
bioenergetics loss and restores mitochondrial dynamics in streptozotocin-induced sporadic dementia of 
Alzheimer’s type. Neurotoxicology 2019, 73, 246–257, doi:10.1016/j.neuro.2019.04.006. 
61. Cassidy-Stone, A.; Chipuk, J.E.; Ingerman, E.; Song, C.; Yoo, C.; Kuwana, T.; Kurth, M.J.; Shaw, J.T.; 
Hinshaw, J.E.; Green, D.R.; et al. Chemical Inhibition of the Mitochondrial Division Dynamin Reveals Its 
Role in Bax/Bak-Dependent Mitochondrial Outer Membrane Permeabilization. Dev. Cell 2008, 14, 193–204, 
doi:10.1016/j.devcel.2007.11.019. 
62. Reddy, P.H.; Manczak, M.; Yin, X. Mitochondria-Division Inhibitor 1 Protects Against Amyloid-β induced 
Mitochondrial Fragmentation and Synaptic Damage in Alzheimer’s Disease. J. Alzheimer’s Dis. 2017, 58, 
147–162, doi:10.3233/JAD-170051. 
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
